In 2012, a large randomized, placebo-controlled trial of chelation (the Trial to Assess Chelation Therapy [TACT]) found a significant benefit for chelation over placebo for composite outcomes (26.5% versus 30% for placebo), but not for individual outcomes (eg, death, cardiovascular events, stroke, hospitalizations) (4).